Medical Care
Global Antibodies in Oncology Market Research Report 2025
- Jul 08, 25
- ID: 348220
- Pages: 75
- Figures: 75
- Views: 1
The global market for Antibodies in Oncology was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Antibodies in Oncology is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Antibodies in Oncology is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Antibodies in Oncology in Hospitals is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Antibodies in Oncology include Novartis International AG, GlaxoSmithKline plc, Biogen Idec Inc., Bristol Myers Squibb Co., AstraZeneca plc., Celltrion, 3SBIO, Celgen Biopharma, Dr Reddy’s, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Antibodies in Oncology, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibodies in Oncology.
The Antibodies in Oncology market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antibodies in Oncology market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibodies in Oncology companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis International AG
GlaxoSmithKline plc
Biogen Idec Inc.
Bristol Myers Squibb Co.
AstraZeneca plc.
Celltrion
3SBIO
Celgen Biopharma
Dr Reddy’s
Segment by Type
Murine Antibodies
Chimeric and Humanised Antibodies
Fully Humanized Antibodies
Others
Segment by Application
Hospitals
Academic Institutes
Clinics
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibodies in Oncology company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
North American market for Antibodies in Oncology is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Antibodies in Oncology is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Antibodies in Oncology in Hospitals is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Antibodies in Oncology include Novartis International AG, GlaxoSmithKline plc, Biogen Idec Inc., Bristol Myers Squibb Co., AstraZeneca plc., Celltrion, 3SBIO, Celgen Biopharma, Dr Reddy’s, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Antibodies in Oncology, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibodies in Oncology.
The Antibodies in Oncology market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antibodies in Oncology market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibodies in Oncology companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis International AG
GlaxoSmithKline plc
Biogen Idec Inc.
Bristol Myers Squibb Co.
AstraZeneca plc.
Celltrion
3SBIO
Celgen Biopharma
Dr Reddy’s
Segment by Type
Murine Antibodies
Chimeric and Humanised Antibodies
Fully Humanized Antibodies
Others
Segment by Application
Hospitals
Academic Institutes
Clinics
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibodies in Oncology company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibodies in Oncology Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Murine Antibodies
1.2.3 Chimeric and Humanised Antibodies
1.2.4 Fully Humanized Antibodies
1.2.5 Others
1.3 Market by Application
1.3.1 Global Antibodies in Oncology Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Academic Institutes
1.3.4 Clinics
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibodies in Oncology Market Perspective (2020-2031)
2.2 Global Antibodies in Oncology Growth Trends by Region
2.2.1 Global Antibodies in Oncology Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Antibodies in Oncology Historic Market Size by Region (2020-2025)
2.2.3 Antibodies in Oncology Forecasted Market Size by Region (2026-2031)
2.3 Antibodies in Oncology Market Dynamics
2.3.1 Antibodies in Oncology Industry Trends
2.3.2 Antibodies in Oncology Market Drivers
2.3.3 Antibodies in Oncology Market Challenges
2.3.4 Antibodies in Oncology Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibodies in Oncology Players by Revenue
3.1.1 Global Top Antibodies in Oncology Players by Revenue (2020-2025)
3.1.2 Global Antibodies in Oncology Revenue Market Share by Players (2020-2025)
3.2 Global Antibodies in Oncology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Antibodies in Oncology Revenue
3.4 Global Antibodies in Oncology Market Concentration Ratio
3.4.1 Global Antibodies in Oncology Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibodies in Oncology Revenue in 2024
3.5 Global Key Players of Antibodies in Oncology Head office and Area Served
3.6 Global Key Players of Antibodies in Oncology, Product and Application
3.7 Global Key Players of Antibodies in Oncology, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibodies in Oncology Breakdown Data by Type
4.1 Global Antibodies in Oncology Historic Market Size by Type (2020-2025)
4.2 Global Antibodies in Oncology Forecasted Market Size by Type (2026-2031)
5 Antibodies in Oncology Breakdown Data by Application
5.1 Global Antibodies in Oncology Historic Market Size by Application (2020-2025)
5.2 Global Antibodies in Oncology Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Antibodies in Oncology Market Size (2020-2031)
6.2 North America Antibodies in Oncology Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Antibodies in Oncology Market Size by Country (2020-2025)
6.4 North America Antibodies in Oncology Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antibodies in Oncology Market Size (2020-2031)
7.2 Europe Antibodies in Oncology Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Antibodies in Oncology Market Size by Country (2020-2025)
7.4 Europe Antibodies in Oncology Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antibodies in Oncology Market Size (2020-2031)
8.2 Asia-Pacific Antibodies in Oncology Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Antibodies in Oncology Market Size by Region (2020-2025)
8.4 Asia-Pacific Antibodies in Oncology Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antibodies in Oncology Market Size (2020-2031)
9.2 Latin America Antibodies in Oncology Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Antibodies in Oncology Market Size by Country (2020-2025)
9.4 Latin America Antibodies in Oncology Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibodies in Oncology Market Size (2020-2031)
10.2 Middle East & Africa Antibodies in Oncology Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Antibodies in Oncology Market Size by Country (2020-2025)
10.4 Middle East & Africa Antibodies in Oncology Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis International AG
11.1.1 Novartis International AG Company Details
11.1.2 Novartis International AG Business Overview
11.1.3 Novartis International AG Antibodies in Oncology Introduction
11.1.4 Novartis International AG Revenue in Antibodies in Oncology Business (2020-2025)
11.1.5 Novartis International AG Recent Development
11.2 GlaxoSmithKline plc
11.2.1 GlaxoSmithKline plc Company Details
11.2.2 GlaxoSmithKline plc Business Overview
11.2.3 GlaxoSmithKline plc Antibodies in Oncology Introduction
11.2.4 GlaxoSmithKline plc Revenue in Antibodies in Oncology Business (2020-2025)
11.2.5 GlaxoSmithKline plc Recent Development
11.3 Biogen Idec Inc.
11.3.1 Biogen Idec Inc. Company Details
11.3.2 Biogen Idec Inc. Business Overview
11.3.3 Biogen Idec Inc. Antibodies in Oncology Introduction
11.3.4 Biogen Idec Inc. Revenue in Antibodies in Oncology Business (2020-2025)
11.3.5 Biogen Idec Inc. Recent Development
11.4 Bristol Myers Squibb Co.
11.4.1 Bristol Myers Squibb Co. Company Details
11.4.2 Bristol Myers Squibb Co. Business Overview
11.4.3 Bristol Myers Squibb Co. Antibodies in Oncology Introduction
11.4.4 Bristol Myers Squibb Co. Revenue in Antibodies in Oncology Business (2020-2025)
11.4.5 Bristol Myers Squibb Co. Recent Development
11.5 AstraZeneca plc.
11.5.1 AstraZeneca plc. Company Details
11.5.2 AstraZeneca plc. Business Overview
11.5.3 AstraZeneca plc. Antibodies in Oncology Introduction
11.5.4 AstraZeneca plc. Revenue in Antibodies in Oncology Business (2020-2025)
11.5.5 AstraZeneca plc. Recent Development
11.6 Celltrion
11.6.1 Celltrion Company Details
11.6.2 Celltrion Business Overview
11.6.3 Celltrion Antibodies in Oncology Introduction
11.6.4 Celltrion Revenue in Antibodies in Oncology Business (2020-2025)
11.6.5 Celltrion Recent Development
11.7 3SBIO
11.7.1 3SBIO Company Details
11.7.2 3SBIO Business Overview
11.7.3 3SBIO Antibodies in Oncology Introduction
11.7.4 3SBIO Revenue in Antibodies in Oncology Business (2020-2025)
11.7.5 3SBIO Recent Development
11.8 Celgen Biopharma
11.8.1 Celgen Biopharma Company Details
11.8.2 Celgen Biopharma Business Overview
11.8.3 Celgen Biopharma Antibodies in Oncology Introduction
11.8.4 Celgen Biopharma Revenue in Antibodies in Oncology Business (2020-2025)
11.8.5 Celgen Biopharma Recent Development
11.9 Dr Reddy’s
11.9.1 Dr Reddy’s Company Details
11.9.2 Dr Reddy’s Business Overview
11.9.3 Dr Reddy’s Antibodies in Oncology Introduction
11.9.4 Dr Reddy’s Revenue in Antibodies in Oncology Business (2020-2025)
11.9.5 Dr Reddy’s Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibodies in Oncology Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Murine Antibodies
1.2.3 Chimeric and Humanised Antibodies
1.2.4 Fully Humanized Antibodies
1.2.5 Others
1.3 Market by Application
1.3.1 Global Antibodies in Oncology Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Academic Institutes
1.3.4 Clinics
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibodies in Oncology Market Perspective (2020-2031)
2.2 Global Antibodies in Oncology Growth Trends by Region
2.2.1 Global Antibodies in Oncology Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Antibodies in Oncology Historic Market Size by Region (2020-2025)
2.2.3 Antibodies in Oncology Forecasted Market Size by Region (2026-2031)
2.3 Antibodies in Oncology Market Dynamics
2.3.1 Antibodies in Oncology Industry Trends
2.3.2 Antibodies in Oncology Market Drivers
2.3.3 Antibodies in Oncology Market Challenges
2.3.4 Antibodies in Oncology Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibodies in Oncology Players by Revenue
3.1.1 Global Top Antibodies in Oncology Players by Revenue (2020-2025)
3.1.2 Global Antibodies in Oncology Revenue Market Share by Players (2020-2025)
3.2 Global Antibodies in Oncology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Antibodies in Oncology Revenue
3.4 Global Antibodies in Oncology Market Concentration Ratio
3.4.1 Global Antibodies in Oncology Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibodies in Oncology Revenue in 2024
3.5 Global Key Players of Antibodies in Oncology Head office and Area Served
3.6 Global Key Players of Antibodies in Oncology, Product and Application
3.7 Global Key Players of Antibodies in Oncology, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibodies in Oncology Breakdown Data by Type
4.1 Global Antibodies in Oncology Historic Market Size by Type (2020-2025)
4.2 Global Antibodies in Oncology Forecasted Market Size by Type (2026-2031)
5 Antibodies in Oncology Breakdown Data by Application
5.1 Global Antibodies in Oncology Historic Market Size by Application (2020-2025)
5.2 Global Antibodies in Oncology Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Antibodies in Oncology Market Size (2020-2031)
6.2 North America Antibodies in Oncology Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Antibodies in Oncology Market Size by Country (2020-2025)
6.4 North America Antibodies in Oncology Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antibodies in Oncology Market Size (2020-2031)
7.2 Europe Antibodies in Oncology Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Antibodies in Oncology Market Size by Country (2020-2025)
7.4 Europe Antibodies in Oncology Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antibodies in Oncology Market Size (2020-2031)
8.2 Asia-Pacific Antibodies in Oncology Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Antibodies in Oncology Market Size by Region (2020-2025)
8.4 Asia-Pacific Antibodies in Oncology Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antibodies in Oncology Market Size (2020-2031)
9.2 Latin America Antibodies in Oncology Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Antibodies in Oncology Market Size by Country (2020-2025)
9.4 Latin America Antibodies in Oncology Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibodies in Oncology Market Size (2020-2031)
10.2 Middle East & Africa Antibodies in Oncology Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Antibodies in Oncology Market Size by Country (2020-2025)
10.4 Middle East & Africa Antibodies in Oncology Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis International AG
11.1.1 Novartis International AG Company Details
11.1.2 Novartis International AG Business Overview
11.1.3 Novartis International AG Antibodies in Oncology Introduction
11.1.4 Novartis International AG Revenue in Antibodies in Oncology Business (2020-2025)
11.1.5 Novartis International AG Recent Development
11.2 GlaxoSmithKline plc
11.2.1 GlaxoSmithKline plc Company Details
11.2.2 GlaxoSmithKline plc Business Overview
11.2.3 GlaxoSmithKline plc Antibodies in Oncology Introduction
11.2.4 GlaxoSmithKline plc Revenue in Antibodies in Oncology Business (2020-2025)
11.2.5 GlaxoSmithKline plc Recent Development
11.3 Biogen Idec Inc.
11.3.1 Biogen Idec Inc. Company Details
11.3.2 Biogen Idec Inc. Business Overview
11.3.3 Biogen Idec Inc. Antibodies in Oncology Introduction
11.3.4 Biogen Idec Inc. Revenue in Antibodies in Oncology Business (2020-2025)
11.3.5 Biogen Idec Inc. Recent Development
11.4 Bristol Myers Squibb Co.
11.4.1 Bristol Myers Squibb Co. Company Details
11.4.2 Bristol Myers Squibb Co. Business Overview
11.4.3 Bristol Myers Squibb Co. Antibodies in Oncology Introduction
11.4.4 Bristol Myers Squibb Co. Revenue in Antibodies in Oncology Business (2020-2025)
11.4.5 Bristol Myers Squibb Co. Recent Development
11.5 AstraZeneca plc.
11.5.1 AstraZeneca plc. Company Details
11.5.2 AstraZeneca plc. Business Overview
11.5.3 AstraZeneca plc. Antibodies in Oncology Introduction
11.5.4 AstraZeneca plc. Revenue in Antibodies in Oncology Business (2020-2025)
11.5.5 AstraZeneca plc. Recent Development
11.6 Celltrion
11.6.1 Celltrion Company Details
11.6.2 Celltrion Business Overview
11.6.3 Celltrion Antibodies in Oncology Introduction
11.6.4 Celltrion Revenue in Antibodies in Oncology Business (2020-2025)
11.6.5 Celltrion Recent Development
11.7 3SBIO
11.7.1 3SBIO Company Details
11.7.2 3SBIO Business Overview
11.7.3 3SBIO Antibodies in Oncology Introduction
11.7.4 3SBIO Revenue in Antibodies in Oncology Business (2020-2025)
11.7.5 3SBIO Recent Development
11.8 Celgen Biopharma
11.8.1 Celgen Biopharma Company Details
11.8.2 Celgen Biopharma Business Overview
11.8.3 Celgen Biopharma Antibodies in Oncology Introduction
11.8.4 Celgen Biopharma Revenue in Antibodies in Oncology Business (2020-2025)
11.8.5 Celgen Biopharma Recent Development
11.9 Dr Reddy’s
11.9.1 Dr Reddy’s Company Details
11.9.2 Dr Reddy’s Business Overview
11.9.3 Dr Reddy’s Antibodies in Oncology Introduction
11.9.4 Dr Reddy’s Revenue in Antibodies in Oncology Business (2020-2025)
11.9.5 Dr Reddy’s Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Antibodies in Oncology Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Murine Antibodies
Table 3. Key Players of Chimeric and Humanised Antibodies
Table 4. Key Players of Fully Humanized Antibodies
Table 5. Key Players of Others
Table 6. Global Antibodies in Oncology Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Antibodies in Oncology Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Antibodies in Oncology Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Antibodies in Oncology Market Share by Region (2020-2025)
Table 10. Global Antibodies in Oncology Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Antibodies in Oncology Market Share by Region (2026-2031)
Table 12. Antibodies in Oncology Market Trends
Table 13. Antibodies in Oncology Market Drivers
Table 14. Antibodies in Oncology Market Challenges
Table 15. Antibodies in Oncology Market Restraints
Table 16. Global Antibodies in Oncology Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Antibodies in Oncology Market Share by Players (2020-2025)
Table 18. Global Top Antibodies in Oncology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibodies in Oncology as of 2024)
Table 19. Ranking of Global Top Antibodies in Oncology Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Antibodies in Oncology Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Antibodies in Oncology, Headquarters and Area Served
Table 22. Global Key Players of Antibodies in Oncology, Product and Application
Table 23. Global Key Players of Antibodies in Oncology, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Antibodies in Oncology Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Antibodies in Oncology Revenue Market Share by Type (2020-2025)
Table 27. Global Antibodies in Oncology Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Antibodies in Oncology Revenue Market Share by Type (2026-2031)
Table 29. Global Antibodies in Oncology Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Antibodies in Oncology Revenue Market Share by Application (2020-2025)
Table 31. Global Antibodies in Oncology Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Antibodies in Oncology Revenue Market Share by Application (2026-2031)
Table 33. North America Antibodies in Oncology Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Antibodies in Oncology Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Antibodies in Oncology Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Antibodies in Oncology Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Antibodies in Oncology Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Antibodies in Oncology Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Antibodies in Oncology Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Antibodies in Oncology Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Antibodies in Oncology Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Antibodies in Oncology Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Antibodies in Oncology Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Antibodies in Oncology Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Antibodies in Oncology Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Antibodies in Oncology Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Antibodies in Oncology Market Size by Country (2026-2031) & (US$ Million)
Table 48. Novartis International AG Company Details
Table 49. Novartis International AG Business Overview
Table 50. Novartis International AG Antibodies in Oncology Product
Table 51. Novartis International AG Revenue in Antibodies in Oncology Business (2020-2025) & (US$ Million)
Table 52. Novartis International AG Recent Development
Table 53. GlaxoSmithKline plc Company Details
Table 54. GlaxoSmithKline plc Business Overview
Table 55. GlaxoSmithKline plc Antibodies in Oncology Product
Table 56. GlaxoSmithKline plc Revenue in Antibodies in Oncology Business (2020-2025) & (US$ Million)
Table 57. GlaxoSmithKline plc Recent Development
Table 58. Biogen Idec Inc. Company Details
Table 59. Biogen Idec Inc. Business Overview
Table 60. Biogen Idec Inc. Antibodies in Oncology Product
Table 61. Biogen Idec Inc. Revenue in Antibodies in Oncology Business (2020-2025) & (US$ Million)
Table 62. Biogen Idec Inc. Recent Development
Table 63. Bristol Myers Squibb Co. Company Details
Table 64. Bristol Myers Squibb Co. Business Overview
Table 65. Bristol Myers Squibb Co. Antibodies in Oncology Product
Table 66. Bristol Myers Squibb Co. Revenue in Antibodies in Oncology Business (2020-2025) & (US$ Million)
Table 67. Bristol Myers Squibb Co. Recent Development
Table 68. AstraZeneca plc. Company Details
Table 69. AstraZeneca plc. Business Overview
Table 70. AstraZeneca plc. Antibodies in Oncology Product
Table 71. AstraZeneca plc. Revenue in Antibodies in Oncology Business (2020-2025) & (US$ Million)
Table 72. AstraZeneca plc. Recent Development
Table 73. Celltrion Company Details
Table 74. Celltrion Business Overview
Table 75. Celltrion Antibodies in Oncology Product
Table 76. Celltrion Revenue in Antibodies in Oncology Business (2020-2025) & (US$ Million)
Table 77. Celltrion Recent Development
Table 78. 3SBIO Company Details
Table 79. 3SBIO Business Overview
Table 80. 3SBIO Antibodies in Oncology Product
Table 81. 3SBIO Revenue in Antibodies in Oncology Business (2020-2025) & (US$ Million)
Table 82. 3SBIO Recent Development
Table 83. Celgen Biopharma Company Details
Table 84. Celgen Biopharma Business Overview
Table 85. Celgen Biopharma Antibodies in Oncology Product
Table 86. Celgen Biopharma Revenue in Antibodies in Oncology Business (2020-2025) & (US$ Million)
Table 87. Celgen Biopharma Recent Development
Table 88. Dr Reddy’s Company Details
Table 89. Dr Reddy’s Business Overview
Table 90. Dr Reddy’s Antibodies in Oncology Product
Table 91. Dr Reddy’s Revenue in Antibodies in Oncology Business (2020-2025) & (US$ Million)
Table 92. Dr Reddy’s Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
Table 96. Authors List of This Report
List of Figures
Figure 1. Antibodies in Oncology Picture
Figure 2. Global Antibodies in Oncology Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Antibodies in Oncology Market Share by Type: 2024 VS 2031
Figure 4. Murine Antibodies Features
Figure 5. Chimeric and Humanised Antibodies Features
Figure 6. Fully Humanized Antibodies Features
Figure 7. Others Features
Figure 8. Global Antibodies in Oncology Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Antibodies in Oncology Market Share by Application: 2024 VS 2031
Figure 10. Hospitals Case Studies
Figure 11. Academic Institutes Case Studies
Figure 12. Clinics Case Studies
Figure 13. Antibodies in Oncology Report Years Considered
Figure 14. Global Antibodies in Oncology Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Antibodies in Oncology Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Antibodies in Oncology Market Share by Region: 2024 VS 2031
Figure 17. Global Antibodies in Oncology Market Share by Players in 2024
Figure 18. Global Top Antibodies in Oncology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibodies in Oncology as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Antibodies in Oncology Revenue in 2024
Figure 20. North America Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Antibodies in Oncology Market Share by Country (2020-2031)
Figure 22. United States Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Antibodies in Oncology Market Share by Country (2020-2031)
Figure 26. Germany Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Antibodies in Oncology Market Share by Region (2020-2031)
Figure 34. China Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Antibodies in Oncology Market Share by Country (2020-2031)
Figure 42. Mexico Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Antibodies in Oncology Market Share by Country (2020-2031)
Figure 46. Turkey Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Novartis International AG Revenue Growth Rate in Antibodies in Oncology Business (2020-2025)
Figure 50. GlaxoSmithKline plc Revenue Growth Rate in Antibodies in Oncology Business (2020-2025)
Figure 51. Biogen Idec Inc. Revenue Growth Rate in Antibodies in Oncology Business (2020-2025)
Figure 52. Bristol Myers Squibb Co. Revenue Growth Rate in Antibodies in Oncology Business (2020-2025)
Figure 53. AstraZeneca plc. Revenue Growth Rate in Antibodies in Oncology Business (2020-2025)
Figure 54. Celltrion Revenue Growth Rate in Antibodies in Oncology Business (2020-2025)
Figure 55. 3SBIO Revenue Growth Rate in Antibodies in Oncology Business (2020-2025)
Figure 56. Celgen Biopharma Revenue Growth Rate in Antibodies in Oncology Business (2020-2025)
Figure 57. Dr Reddy’s Revenue Growth Rate in Antibodies in Oncology Business (2020-2025)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Table 1. Global Antibodies in Oncology Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Murine Antibodies
Table 3. Key Players of Chimeric and Humanised Antibodies
Table 4. Key Players of Fully Humanized Antibodies
Table 5. Key Players of Others
Table 6. Global Antibodies in Oncology Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Antibodies in Oncology Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Antibodies in Oncology Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Antibodies in Oncology Market Share by Region (2020-2025)
Table 10. Global Antibodies in Oncology Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Antibodies in Oncology Market Share by Region (2026-2031)
Table 12. Antibodies in Oncology Market Trends
Table 13. Antibodies in Oncology Market Drivers
Table 14. Antibodies in Oncology Market Challenges
Table 15. Antibodies in Oncology Market Restraints
Table 16. Global Antibodies in Oncology Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Antibodies in Oncology Market Share by Players (2020-2025)
Table 18. Global Top Antibodies in Oncology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibodies in Oncology as of 2024)
Table 19. Ranking of Global Top Antibodies in Oncology Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Antibodies in Oncology Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Antibodies in Oncology, Headquarters and Area Served
Table 22. Global Key Players of Antibodies in Oncology, Product and Application
Table 23. Global Key Players of Antibodies in Oncology, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Antibodies in Oncology Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Antibodies in Oncology Revenue Market Share by Type (2020-2025)
Table 27. Global Antibodies in Oncology Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Antibodies in Oncology Revenue Market Share by Type (2026-2031)
Table 29. Global Antibodies in Oncology Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Antibodies in Oncology Revenue Market Share by Application (2020-2025)
Table 31. Global Antibodies in Oncology Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Antibodies in Oncology Revenue Market Share by Application (2026-2031)
Table 33. North America Antibodies in Oncology Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Antibodies in Oncology Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Antibodies in Oncology Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Antibodies in Oncology Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Antibodies in Oncology Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Antibodies in Oncology Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Antibodies in Oncology Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Antibodies in Oncology Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Antibodies in Oncology Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Antibodies in Oncology Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Antibodies in Oncology Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Antibodies in Oncology Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Antibodies in Oncology Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Antibodies in Oncology Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Antibodies in Oncology Market Size by Country (2026-2031) & (US$ Million)
Table 48. Novartis International AG Company Details
Table 49. Novartis International AG Business Overview
Table 50. Novartis International AG Antibodies in Oncology Product
Table 51. Novartis International AG Revenue in Antibodies in Oncology Business (2020-2025) & (US$ Million)
Table 52. Novartis International AG Recent Development
Table 53. GlaxoSmithKline plc Company Details
Table 54. GlaxoSmithKline plc Business Overview
Table 55. GlaxoSmithKline plc Antibodies in Oncology Product
Table 56. GlaxoSmithKline plc Revenue in Antibodies in Oncology Business (2020-2025) & (US$ Million)
Table 57. GlaxoSmithKline plc Recent Development
Table 58. Biogen Idec Inc. Company Details
Table 59. Biogen Idec Inc. Business Overview
Table 60. Biogen Idec Inc. Antibodies in Oncology Product
Table 61. Biogen Idec Inc. Revenue in Antibodies in Oncology Business (2020-2025) & (US$ Million)
Table 62. Biogen Idec Inc. Recent Development
Table 63. Bristol Myers Squibb Co. Company Details
Table 64. Bristol Myers Squibb Co. Business Overview
Table 65. Bristol Myers Squibb Co. Antibodies in Oncology Product
Table 66. Bristol Myers Squibb Co. Revenue in Antibodies in Oncology Business (2020-2025) & (US$ Million)
Table 67. Bristol Myers Squibb Co. Recent Development
Table 68. AstraZeneca plc. Company Details
Table 69. AstraZeneca plc. Business Overview
Table 70. AstraZeneca plc. Antibodies in Oncology Product
Table 71. AstraZeneca plc. Revenue in Antibodies in Oncology Business (2020-2025) & (US$ Million)
Table 72. AstraZeneca plc. Recent Development
Table 73. Celltrion Company Details
Table 74. Celltrion Business Overview
Table 75. Celltrion Antibodies in Oncology Product
Table 76. Celltrion Revenue in Antibodies in Oncology Business (2020-2025) & (US$ Million)
Table 77. Celltrion Recent Development
Table 78. 3SBIO Company Details
Table 79. 3SBIO Business Overview
Table 80. 3SBIO Antibodies in Oncology Product
Table 81. 3SBIO Revenue in Antibodies in Oncology Business (2020-2025) & (US$ Million)
Table 82. 3SBIO Recent Development
Table 83. Celgen Biopharma Company Details
Table 84. Celgen Biopharma Business Overview
Table 85. Celgen Biopharma Antibodies in Oncology Product
Table 86. Celgen Biopharma Revenue in Antibodies in Oncology Business (2020-2025) & (US$ Million)
Table 87. Celgen Biopharma Recent Development
Table 88. Dr Reddy’s Company Details
Table 89. Dr Reddy’s Business Overview
Table 90. Dr Reddy’s Antibodies in Oncology Product
Table 91. Dr Reddy’s Revenue in Antibodies in Oncology Business (2020-2025) & (US$ Million)
Table 92. Dr Reddy’s Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
Table 96. Authors List of This Report
List of Figures
Figure 1. Antibodies in Oncology Picture
Figure 2. Global Antibodies in Oncology Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Antibodies in Oncology Market Share by Type: 2024 VS 2031
Figure 4. Murine Antibodies Features
Figure 5. Chimeric and Humanised Antibodies Features
Figure 6. Fully Humanized Antibodies Features
Figure 7. Others Features
Figure 8. Global Antibodies in Oncology Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Antibodies in Oncology Market Share by Application: 2024 VS 2031
Figure 10. Hospitals Case Studies
Figure 11. Academic Institutes Case Studies
Figure 12. Clinics Case Studies
Figure 13. Antibodies in Oncology Report Years Considered
Figure 14. Global Antibodies in Oncology Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Antibodies in Oncology Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Antibodies in Oncology Market Share by Region: 2024 VS 2031
Figure 17. Global Antibodies in Oncology Market Share by Players in 2024
Figure 18. Global Top Antibodies in Oncology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibodies in Oncology as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Antibodies in Oncology Revenue in 2024
Figure 20. North America Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Antibodies in Oncology Market Share by Country (2020-2031)
Figure 22. United States Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Antibodies in Oncology Market Share by Country (2020-2031)
Figure 26. Germany Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Antibodies in Oncology Market Share by Region (2020-2031)
Figure 34. China Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Antibodies in Oncology Market Share by Country (2020-2031)
Figure 42. Mexico Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Antibodies in Oncology Market Share by Country (2020-2031)
Figure 46. Turkey Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Antibodies in Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Novartis International AG Revenue Growth Rate in Antibodies in Oncology Business (2020-2025)
Figure 50. GlaxoSmithKline plc Revenue Growth Rate in Antibodies in Oncology Business (2020-2025)
Figure 51. Biogen Idec Inc. Revenue Growth Rate in Antibodies in Oncology Business (2020-2025)
Figure 52. Bristol Myers Squibb Co. Revenue Growth Rate in Antibodies in Oncology Business (2020-2025)
Figure 53. AstraZeneca plc. Revenue Growth Rate in Antibodies in Oncology Business (2020-2025)
Figure 54. Celltrion Revenue Growth Rate in Antibodies in Oncology Business (2020-2025)
Figure 55. 3SBIO Revenue Growth Rate in Antibodies in Oncology Business (2020-2025)
Figure 56. Celgen Biopharma Revenue Growth Rate in Antibodies in Oncology Business (2020-2025)
Figure 57. Dr Reddy’s Revenue Growth Rate in Antibodies in Oncology Business (2020-2025)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Advanced Enteric Capsules Market Research Report 2025
Jul 08, 25
Global Outdoor Structures and Chairs Market Research Report 2025
Jul 08, 25
Global Herbs Ingredients Market Research Report 2025
Jul 08, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232